Researchers report the 5-year survival outcomes with lisocabtagene maraleucel in heavily pretreated patients with relapsed or refractory LBCL in the TRANSCEND study.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/does-liso-cel-offer-long-term-survival-benefits-r-r-lbcl-2026a1000lsk?src=rss
Author :
Publish date : 2026-06-26 11:22:00
Copyright for syndicated content belongs to the linked Source.
